Sökning: WFRF:(Abrahamsson Jonas 1954)
> (2020-2024) >
Molecular Measurabl...
Molecular Measurable Residual Disease Assessment before Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia Patients: A Retrospective Study by the I-BFM Study Group
-
Benetton, M. (författare)
-
Merli, P. (författare)
-
Walter, C. (författare)
-
visa fler...
-
Hansen, M. (författare)
-
Da Ros, A. (författare)
-
Polato, K. (författare)
-
Tregnago, C. (författare)
-
- Abrahamsson, Jonas, 1954 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för pediatrik,Institute of Clinical Sciences, Department of Pediatrics
-
Strocchio, L. (författare)
-
Sonneveld, E. (författare)
-
- Fogelstrand, Linda, 1974 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för laboratoriemedicin,Department of Laboratory Medicine
-
Von Neuhoff, N. (författare)
-
Reinhardt, D. (författare)
-
Hasle, H. (författare)
-
Pigazzi, M. (författare)
-
Locatelli, F. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2022-06-28
- 2022
- Engelska.
-
Ingår i: Biomedicines. - : MDPI AG. - 2227-9059. ; 10:7
- Relaterad länk:
-
https://gup.ub.gu.se...
-
visa fler...
-
https://doi.org/10.3...
-
visa färre...
Abstract
Ämnesord
Stäng
- Hematopoietic stem cell transplantation (HSCT) is a curative post-remission treatment in patients with acute myeloid leukemia (AML), but relapse after transplant is still a challenging event. In recent year, several studies have investigated the molecular minimal residual disease (qPCR-MRD) as a predictor of relapse, but the lack of standardized protocols, cut-offs, and timepoints, especially in the pediatric setting, has prevented its use in several settings, including before HSCT. Here, we propose the first collaborative retrospective I-BFM-AML study assessing qPCR-MRD values in pretransplant bone marrow samples of 112 patients with a diagnosis of AML harboring t(8;21)(q22; q22)RUNX1::RUNX1T1, or inv(16)(p13q22)CBFB::MYH11, or t(9;11)(p21;q23)KMT2A::MLLT3, or FLT3-ITD genetic markers. We calculated an ROC cut-off of 2.1 x 10(-4) that revealed significantly increased OS (83.7% versus 57.1%) and EFS (80.2% versus 52.9%) for those patients with lower qPCR-MRD values. Then, we partitioned patients into three qPCR-MRD groups by combining two different thresholds, 2.1 x 10(-4) and one lower cut-off of 1 x 10(-2), and stratified patients into low-, intermediate-, and high-risk groups. We found that the 5-year OS (83.7%, 68.6%, and 39.2%, respectively) and relapse-free survival (89.2%, 73.9%, and 67.9%, respectively) were significantly different independent of the genetic lesion, conditioning regimen, donor, and stem cell source. These data support the PCR-based approach playing a clinical relevance in AML transplant management.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Pediatrik (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Pediatrics (hsv//eng)
Nyckelord
- AML
- HSCT
- q-PCR
- MRD
- molecular genetics
- fusion gene transcripts
- aieop-aml 2002/01
- randomized-trial
- rt-pcr
- children
- therapy
- mrd
- standardization
- recommendations
- aberrations
- Biochemistry & Molecular Biology
- Research & Experimental Medicine
- Pharmacology & Pharmacy
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Benetton, M.
-
Merli, P.
-
Walter, C.
-
Hansen, M.
-
Da Ros, A.
-
Polato, K.
-
visa fler...
-
Tregnago, C.
-
Abrahamsson, Jon ...
-
Strocchio, L.
-
Sonneveld, E.
-
Fogelstrand, Lin ...
-
Von Neuhoff, N.
-
Reinhardt, D.
-
Hasle, H.
-
Pigazzi, M.
-
Locatelli, F.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Pediatrik
- Artiklar i publikationen
-
Biomedicines
- Av lärosätet
-
Göteborgs universitet